abbott posit defend
despit weak medic devic
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
follow integr st jude medic abbott
continu improv profit segment nutrit
devic diagnost establish pharmaceut although
abbott made progress last seven year still lag
key rival profit measur despit compet
busi character attract margin
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott freestyl libr blood glucos
monitor one compel innov firm ever
launch like abbott substanti footprint latin
america russia establish pharmaceut product
lead faster growth brand gener
addit st jude heart-focus portfolio along smaller
offer rais firm abil compet hospit client
seek winnow supplier
fuel
med-tech compani abbott big challeng
innov bar secur
reimburs new technolog risen payer
becom stringent clinic data commit
payment abbott seen recent success freestyl
libr less impress histor track record new
product launch compar key medic devic competitor
includ
abbott cultiv similar revolutionari advanc
firm fort seem focu around increment improv
exist technolog platform acquir last
year thank healthcar reform approach less like
yield robust return futur
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net incom averag number common
abbott manufactur market medic devic adult pediatr
nutrit product diagnost equip test kit brand
formula nutrit liquid adult immunoassay point-of-car
diagnost equip abbott deriv approxim sale outsid
unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
abbott posit defend
despit weak medic devic apr
quarter result strength consumer-fac
segment offset declin key medic
devic categori elect procedur
crowd crisi incorpor
estim impact cash flow assumpt
modestli lower fair valu estim
per share among med-tech compani think
narrow-moat abbott well posit weather
pandem thank divers rang product especi
consumer-ori busi first-quart organ top-
line growth support strength
nutrit establish pharmaceut busi
year year
probabl disturb usual time pediatr
nutrit purchas consum sought buy
extra formula shelter-in-plac order came still
expect see robust growth segment full year
anticip medic devic saw declin
first quarter hospit postpon elect procedur
order accommod expect wave
patient though wed expect soft
cardiac devic franchis magnitud
declin nonetheless startl us year year
 sale cardiac rhythm manag electrophysiolog
vascular fell respect overal
wed expect orthoped devic maker absorb
greater impact joint replac gener
elect cardiac procedur howev johnson
 johnson saw hip knee declin roughli
first quarter clear cardiac
categori declin even faster hip knee
better sens
report next coupl week
abbott diagnost unit perhap
interest consid role firm play
develop new test ramp
diagnost capac one hand saw soft
core lab like relat crowd elect
procedur volum reli chemistri hematolog
transfus panel hand molecular rapid
diagnost saw strength year year
respect thank roll-out lab-bas
point-of-car test anticip growth
second quarter test adopt scale
firm also launch new antibodi
test also see quick adopt second
third quarter
diagnost test viru continu
bottleneck state attempt get handl extent
transmiss plan next step eventu safe
allow resid emerg home good news
center medicar medicaid servic
approxim doubl reimburs rate
test order encourag practition
test wide howev believ
constraint suppli labor lab capac logist
prevent us test extens public
health offici advoc better manag crisi
modestli decreas fair valu estim
per share reflect expect
crowd elect procedur damp growth
certain cardiac devic categori partial off-set
stronger growth diagnost freestyl libr
pediatr nutrit near term longer time
frame anticip robust top-lin growth
driven new product launch remain optimist
key growth driver expect penetr larg
underserv patient popul continu expect
top-lin strength domest launch freestyl
libr on-going adopt alin system
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv
firm leverag distribut infrastructur
built penetr emerg market across
product segment extract cost synergi
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium
bullish scenario put abbott valu per
share case assum impact
mild abbott averag top-lin growth
thank stronger-than-expect perform
diagnost nutrit cardiac care area
assum outsiz gain pediatr adult nutrit
intern double-digit growth structur heart
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag shi annual
assum greater impact near term
declin stent sale boston scientif
offer superior technolog long haul
mute perform mitraclip edward enter
domest market low-single-digit growth nutrit
low-single-digit growth diagnost assum
abbott rais oper margin
comprehens test panel innov structur
heart heart failur electrophysiolog
neuromodul area weak
competitor introduc new product think
segment return growth delay
pandem eventu see growth
elect procedur volum normal project
revenu growth dip return
averag annual growth time frame
revisit abbott perform last financi
crisi assum signific drop profit
longer term anticip firm
resum effort improv profit key
busi turn key factor
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
think addit st jude portfolio cardiac devic
push abbott toward wider side narrow moat
fulli convinc abbott tip
wide moat categori especi firm nurtur
kind on-going occasion revolutionari
innov necessari secur reimburs
longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent venou closur devic
immunoassay market abbott particip
ration oligopoli enjoy benefit intang
think nutrit busi one moatiest
part abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
nutrit busi think agreement fonterra
may help abbott lower nutrit cost input china
believ substanti enough qualifi
moat sourc
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment sold
outsid busi frequent call brand
gener oper like consum busi
gener mainli sold less develop market
often lack well-develop infrastructur distribut
instead abbott must sell product directli pharmaci
chain physician result brand recognit
reput key factor abbott leverag sell
fragment market also translat less price
pressur abbott could chang longer term
emerg market turn tender system
character develop nation howev chang
remain
cardiac
think abbott benefit consider addit
manag structur heart heart failur howev
juri still abbott abil nurtur renew
innov area long haul thu far abbott
done credibl job commerci alreadi
st jude pipelin less confid abbott
gener greater leap innov base track
record earlier acquisit
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
trend anticip strength coronari stent left
pharmaceut divis diabet busi
neuromodul molecular diagnost busi
off-set current weak
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oearli result investig clinic trial
transcathet mitral valv
tendyn
favor pivot trial result favor
could give boost abbott structur heart unit
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face crowd field molecular
diagnost arena must go head-to-head
market leader roch along energet
competitor like
oslow growth fall birth rate china offer
abbott nutrit
segment could damp nutrit firm
final overcam regulatori chang china
drag growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
abbott balanc sheet solid weather
crisi eas perspect larg
acquisit st jude medic aler increas
leverag abbott enjoy less financi flexibl
time period remain steadi enough
meet debt oblig continu rais dividend
sale vision-car busi purchas
st jude abbott debt/ebitda hover around
time end sinc manag
brought debt level time end
remain comfort abbott estim
interest coverag ebitda/interest time
coverag rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium near term
crisi like delay procedur involv
cardiac devic implant defibril ablat
atrial fibril coronari stent block arteri
neuromodul parkinson like compani
involv medic technolog abbott vulner
threat revolutionari innov rival
particularli issu medic devic diagnost
busi disrupt technolog often emerg
despit abbott recent effort better insul
recal like infant formula recal china
risk product qualiti issu recal remain
damag firm brand relationship medic
profession hospit custom payer
pressur furthermor hospit trend toward bundl
multilin contract expand beyond cardiac therapeut
area abbott could find disadvantag compar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key rival johnson
johnson final abbott oper scrutini
 food drug administr well regulatori
agenc oversea lead delay product
approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
american fund growth fund amer
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit piram st jude
medic remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white recent step ceo role
held sinc new ceo robert ford abbott
first major manag chang two decad though
white remain chairman board point
expect signific chang strateg focu
ford abbott sinc bring
wide-rang experi across differ function
divis nonetheless one hallmark white tenur
raft activ suggest level comfort
kind financi engin perspect
though anticip abbott continu engag
level order augment intern innov
curiou prospect strateg
acquisit technolog ford
independ
board strike us bit unwieldi
execut publicli trade firm chicago area
particularli pleas see stark former ceo
st jude join board expect experi
lead st jude ramp innov could posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
influenc abbott said think room
improv compens polici -- move away
benchmark involv adjust earn per share
ebit measur focus return invest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
abbott posit defend
despit weak medic devic apr
quarter result strength consumer-fac
segment offset declin key medic
devic categori elect procedur
crowd crisi incorpor
estim impact cash flow assumpt
modestli lower fair valu estim
per share among med-tech compani think
narrow-moat abbott well posit weather
pandem thank divers rang product especi
consumer-ori busi first-quart organ top-
line growth support strength
nutrit establish pharmaceut busi
year year
probabl disturb usual time pediatr
nutrit purchas consum sought buy
extra formula shelter-in-plac order came still
expect see robust growth segment full year
anticip medic devic saw declin
first quarter hospit postpon elect procedur
order accommod expect wave
patient though wed expect soft
cardiac devic franchis magnitud
declin nonetheless startl us year year
 sale cardiac rhythm manag electrophysiolog
vascular fell respect overal
wed expect orthoped devic maker absorb
greater impact joint replac gener
elect cardiac procedur howev johnson
 johnson saw hip knee declin roughli
first quarter clear cardiac
categori declin even faster hip knee
better sens
report next coupl week
abbott diagnost unit perhap
interest consid role firm play
develop new test ramp
diagnost capac one hand saw soft
core lab like relat crowd elect
procedur volum reli chemistri hematolog
transfus panel hand molecular rapid
diagnost saw strength year year
respect thank roll-out lab-bas
point-of-car test anticip growth
second quarter test adopt scale
firm also launch new antibodi
test also see quick adopt second
third quarter
diagnost test viru continu
bottleneck state attempt get handl extent
transmiss plan next step eventu safe
allow resid emerg home good news
center medicar medicaid servic
approxim doubl reimburs rate
test order encourag practition
test wide howev believ
constraint suppli labor lab capac logist
prevent us test extens public
health offici advoc better manag crisi
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
year abbott revenu ran ahead project
roughli basi point stronger-than-expect
growth cardiac rhythm manag adult nutrit
off-set softer growth establish pharmaceut
electrophysiolog abbott kept tight hold cost
put oper margin full year close
estim remain confid abbott narrow econom
moat stem intang asset switch
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
abbott lab finish strong fourth-quart
result weve given moder boost fair valu
estim reflect expect robust top-lin
growth firm cue new product launch
seen previou quarter impress revenu
growth fourth quarter driven continu
strength new alin diagnost platform mitraclip
mitral regurgit freestyl libr continu
glucos monitor system expect sustain growth
look forward next year thank
expect launch libr roll-out alin
unit state like indic expans
mitraclip intermediate-risk patient anticip
topspin technolog
abbott cooper insulin pump manufactur tandem
integr libr alter mitraclip platform use
tricuspid valv repair diabet front think
collabor tandem allow freestyl libr
move type market could put pressur rival
hasnt strateg prioriti abbott
thu far also like prospect penetr tricuspid
valv repair -- market histor reli
medic surgeri treatment option though
tricuspid patient pool significantli smaller mitral
pool anticip transcathet altern could
captur consider slice patient
although signific strength behind adopt
mitraclip point wouldnt count competitor
edward lifesci yet remain fan edward
pascal transcathet mitral repair product believ
design easier use abbott advantag sizabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
head start edward prove doesnt need enter
market first ultim win basi superior
technolog reason care watch
uptak pascal europ
abbott manag express confid portico
transcathet aortic valv replac also
contributor revenu growth midterm
expect product receiv domest regulatori approv
later year howev less optimist
prospect market base anem
perform europ estim edward remain
tavr market leader europ follow close
two competitor hold
share geographi remain abbott
boston lotu valv
re-ent market featur novel deploy
mechan reposit properti anticip
intervent cardiologist interest tri
portico skeptic product carv
durabl share surpris
abbott need price aggress spur trial
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
